Skip to main content

Table 1 Characteristics of the studies included in the meta-analysis

From: A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis

First author

Year

Country

NAFLD criteria

PCOS criteria

PCOS (NAFLD)a

Control (NAFLD)#

NOSb

Cerda C

2007

Chile

Ultrasound

Rotterdam

41 (17)

31 (6)

5

Markou A

2010

Greece

Ultrasound

Rotterdam

17 (0)

17 (0)

6

Gutierrez-Grobe Y

2010

Mexico

Ultrasound

Not mentioned

50 (31)

147 (62)

4

Vassilatou E

2010

Greece

Ultrasound

AES

57 (21)

60 (12)

5

Hossain N

2011

USA

Histology

Rotterdam

25 (11)

25 (5)

5

Zueff LF

2012

Brazil

Ultrasound

Rotterdam

45 (33)

45 (21)

5

Karoli R

2013

India

Ultrasound

Rotterdam

54 (36)

55 (14)

5

Qu Z

2013

China

Ultrasound

Rotterdam

602 (198)

588 (109)

5

Kahal H

2014

UK

Ultrasound

Rotterdam

19 (7)

17 (0)

6

Bohdanowicz-Pawlak A

2014

Poland

Ultrasound

Rotterdam

184 (106)

125 (62)

5

Kuliczkowska Plaksej J

2014

Poland

Ultrasound

Rotterdam

173 (92)

125 (40)

5

Romanowski MD

2015

Brazil

Ultrasound

AES

101 (24)

30 (1)

5

Vassilatou E

2015

Greece

Ultrasound

Rotterdam

40 (31)

70 (40)

6

Macut D

2016

Greece Serbia

NAFLD-LFS

Rotterdam

600 (304)

125 (43)

5

Ayonrinde OT

2016

Australia

Ultrasound

NIH

32 (12)

167 (25)

5

Jie C

2017

China

Ultrasound

Rotterdam

400 (225)

100 (38)

5

Kim JJ

2017

Korea

Ultrasound

Rotterdam

275 (15)

892 (25)

6

  1. AES: Androgen Excess Society criteria
  2. NAFLD-LFS: NAFLD liver fat score
  3. aPCOS (NAFLD) means the total number of PCOS and the number of NAFLD in PCOS group
  4. #control (NAFLD) means the total number of control and the number of NAFLD in control group
  5. bThe quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) and the score ranged between 0 and 9